AbbVie agreed to offer Humira through the government direct-to-consumer platform TrumpRx at around $950 per month, alongside other discounted AbbVie products, in the context of tariff and price-control policy risk. The reported discount level is designed to secure an exemption from tariffs and future price mandates tied to participation in TrumpRx. According to reporting cited in the story, Humira access on TrumpRx is restricted to patients without insurance coverage or whose plans do not cover the medications. The policy follows the White House’s push to lower prescription drug prices through Most Favored Nation-style approaches and platform-based discounts. For biopharma commercial teams, the TrumpRx step indicates that pricing exposure can be managed through program participation tied to federal policy concessions—while uncertainty remains for companies that do not secure similar arrangements.